Skip to main content
. Author manuscript; available in PMC: 2022 Nov 19.
Published in final edited form as: J Alzheimers Dis. 2021;82(2):841–853. doi: 10.3233/JAD-210313

Table 1 -.

Summary of demographic, clinical, and cognitive characteristics

NOTCH3
carriers b
(CADASIL)
n=20
PSEN1
carriers a
(ADAD)
n=20
Non-
carriers c

n=45
Demographics
Age 43.92 (6.89) 37.80 (4.40) 41.95 (7.16) a<b *
Female, n (%) 15 (75) 9 (45) 16 (36) b>c **
Education years 9.65 (4.36) 8.75 (3.46) 9.27 (4.72)
Cardiovascular risk factors
Systolic BP 122.05 (14.56) 117.0 (9.27) 120.35 (14.18)
Hypertension treatment, n (%) 3 (15) 0 (0) 5 (25)
Diabetes, n (%) 0 (0) 0 (0) 0 (0)
BMI 26.87 (3.92) 26.04 (6.71) 26.05 (4.47)
Tobacco use, n (%) 2 (10) 7 (35) 10 (22)
FCRP score 4.77 (3.77) 3.72 (2.62) 4.72 (3.91)
Neuropsychological performance
MMSE 28.80 (2.42) 28.05 (1.00) 29.22 (0.85) a<c **
CERAD Total Score 76.90 (10.41) 76.70 (8.89) 82.31 (7.44) a<c ** , b<c **
Memory Composite −0.62 (1.24) −0.83 (1.18) 0.00 (0.79) a<c ** , b<c *
Language Composite −0.36 (1.39) −0.25 (0.92) 0.00 (0.85)
Processing Composite −1.01 (2.29) −0.21 (0.52) 0.00 (0.88) b<c **
Executive Function Composite −0.98 (1.55) −0.16 (0.72) 0.00 (0.70) b<a * , b<c ***

Presented values are mean ± SD, unless otherwise specified. n (%) = number of subjects presenting with the listed condition (representative percentage of the group). Group differences on continuous variable (age, years of education, systolic blood pressure, body-mass index -BMI) were assessed using one-way ANOVAs, with the Bonferroni’s post-hoc tests. Group differences on dichotomous variables (sex, hypertension treatment, diabetes, and tobacco use) were assessed using chi-square tests. Group differences on the Framingham Risk Profile (FCRP) score were assessed using an ANCOVA, controlling for age and sex, with the Bonferroni’s post-hoc tests. Group differences in cognitive performance (MMSE, CERAD Total Score and domain-specific cognitive scores) were assessed using ANCOVAs, controlling for age and education, with the Bonferroni’s post-hoc tests. Because domain-specific cognitive scores were obtained using the performance of the non-carriers group as a reference, the mean for non-carriers on all domain-specific composite scores is 0.

a=

presymptomatic Autosomal dominant Alzheimer’s Disease (ADAD) group

b=

presymptomatic CADASIL group

c=

non-carriers group

*=

p<0.05

**=

p<0.01

***=

p<0.001